Welcome to BioMatics, Inc.

Currently, the major challenge in wound therapy is that chronic wound treatment techniques are limited to visual assessment, by physicians and health care providers, and subjective analysis that results in inconsistencies and treatment bias. There is a clear need for advanced therapy guidance for use by the health care professionals treating difficult chronic wounds.

The solution is BioMatics’ product – Image Guided Wound Therapy – that is currently under development. It is being designed to depict healthy and diseased tissue in chronic wounds. BioMatics’ Image Guided Wound Therapy is being developed to work on virtually any wound type on any part of the body. It is anticipated our product, a non-invasive, hyperspectral digital image data assessment, will provide the treating physician with accurate, reliable data for more efficient and effective wound bed treatment. We are working to rapidly map the healthy and diseased portions of the wound bed.

BioMatics is a developer of bioimaging products as well as a provider of quantitative digital image analysis for histopathological and related biomedical application.

Our latest development assesses hyperspectral images of chronic wounds and provides treating practioners with accurate, reliable data for more efficient and effective treatment of chronic wounds.

BioMatics is involved in Automated Feature Extraction (AFE) technology development for biomedical applications. BioMatics is currently working on proof-of-concept of the efficiency of advanced imaging techniques in a photocarcinogenesis study underway at the National Center for Toxicological Research.

Our product readiness is being developed based on current participation in an independent human clinical trial at the St. Luke’s Medical Center in Milwaukee, Wisconsin. The clinical trial is ongoing and we expect a virtual prototype demo by Quarter 3 of 2006.

BioMatics is at the forefront of the explosive technological changes affecting histopathologic research and biomedical applications. Applications of hyperspectral technologies are emerging in many healthcare and medical research arenas. BioMatics is now perfecting techniques to assist practitioners in managing the hyperspectral raw datasets. We employ powerful spectral processing techniques to analyze and store specific tissue features.

Our target market is the $25 billion chronic wound healing industry. Our country’s aging population, an increase in the incidence of diabetes and other debilitating illnesses and the expanding need for and use of extended care and assisted living facilities for the elderly is driving growth in the vital wound healing market. more

Our company was founded in 2003. We are currently in full product development and are participating in a major clinical study of chronic wound healing. We have recruited the Institute for Technology Development (ITD) at the Stennis Space Center in Mississippi to provide medical hyperspectral sensor equipment for our use in product development. ITD is a leading developer of hyperspectral sensor technology and is providing the sensor equipment for our clinical studies. Our company has extensive experience in hyperspectral analysis for non-medical purposes that provides our core technology and we have one of the country’s leading wound healing practitioners as a partner. Our strategy is to combine these two strengths to launch our product in a rollout in early 2007.